Q04206 (TF65_HUMAN) Homo sapiens (Human)
Transcription factor p65 UniProtKBInterProSTRINGInteractive Modelling
551 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4);
1 identical sequence: Gorilla gorilla gorilla: G3SHV6
Available Structures
88 Experimental Structures
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX |
Heteromer P19838; P25963; | 99.66 | ||||
Crystal Structure of NFkB, IRF7, IRF3 bound to the interferon-b enhancer |
Heteromer P19838; Q14653; Q92985; | 100 | ||||
Crystal structure of a higher-order complex of p50:RelA bound to the HIV-1 LTR |
Heteromer P19838; | 97.43 | ||||
NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the transacti… |
Heteromer P32776; | 96.77 | ||||
NMR structure of the complex between the KIX domain of CBP and the transactivation domain 1 of p65 |
Heteromer P45481; | 96.77 | ||||
Structure of importin a3 bound to the p50- and p65-NLSs |
Heteromer O00629; P19838; | 100 | ||||
solution structures of BRD4 second bromodomain with NF-kB-K310ac peptide |
Heteromer O60885; | 100 | ||||
14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005 |
Heteromer P31947; | 88.89 | 2×CL; 2×0V4; | |||
14-3-3 sigma with RelA/p65 binding site pS45 |
Heteromer P31947; | 88.89 | 4×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192 |
Heteromer P31947; | 88.89 | 2×V2N; 2×V2K; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046 |
Heteromer P31947; | 88.89 | 4×CL; 2×V0T; 2×CA; 2×GOL; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180 |
Heteromer P31947; | 88.89 | 2×TVB; 6×CA; 4×CL; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187 |
Heteromer P31947; | 88.89 | 2×TW8; 4×CA; 2×CL; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185 |
Heteromer P31947; | 88.89 | 2×UT8; 4×CL; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184 |
Heteromer P31947; | 88.89 | 2×UVK; 2×CL; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182 |
Heteromer P31947; | 88.89 | 2×UVZ; 4×CL; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188 |
Heteromer P31947; | 88.89 | 2×UST; 4×CL; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183 |
Heteromer P31947; | 88.89 | 2×UVE; 4×CL; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179 |
Heteromer P31947; | 88.89 | 2×TQW; 2×GOL; 4×CA; 2×CL; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181 |
Heteromer P31947; | 88.89 | 2×UVQ; 4×CL; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186 |
Heteromer P31947; | 88.89 | 2×USW; 4×CL; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521 |
Heteromer P31947; | 88.89 | 2×L3Y; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009 |
Heteromer P31947; | 88.89 | 2×TJ8; 2×MG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069 |
Heteromer P31947; | 88.89 | 2×CL; 2×TZH; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111 |
Heteromer P31947; | 88.89 | 2×UON; 2×UOT; 2×PEG; 2×CL; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134 |
Heteromer P31947; | 88.89 | 2×UVH; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135 |
Heteromer P31947; | 88.89 | 2×UHQ; 4×GOL; 2×CA; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154 |
Heteromer P31947; | 88.89 | 2×TZW; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131 |
Heteromer P31947; | 88.89 | 2×UVB; 2×MG; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125 |
Heteromer P31947; | 88.89 | 2×UWH; 2×CA; 2×CL; 4×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124 |
Heteromer P31947; | 88.89 | 2×UGN; 2×CA; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142 |
Heteromer P31947; | 88.89 | 2×TWQ; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117 |
Heteromer P31947; | 88.89 | 2×V0W; 2×CL; 2×MG; 6×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116 |
Heteromer P31947; | 88.89 | 4×CL; 2×CA; 2×GOL; 2×PEG; 2×V1K; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130 |
Heteromer P31947; | 88.89 | 2×UVN; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120 |
Heteromer P31947; | 88.89 | 2×UXN; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083 |
Heteromer P31947; | 88.89 | 6×V48; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097 |
Heteromer P31947; | 88.89 | 2×V42; 2×CA; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133 |
Heteromer P31947; | 88.89 | 2×UGE; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080 |
Heteromer P31947; | 88.89 | 2×V4N; 2×CL; 2×CA; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096 |
Heteromer P31947; | 88.89 | 2×V3Z; 2×CL; 2×CA; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127 |
Heteromer P31947; | 88.89 | 2×UVT; 2×CL; 2×MG; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126 |
Heteromer P31947; | 88.89 | 2×UHN; 2×CA; 2×CL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070 |
Heteromer P31947; | 88.89 | 2×GOL; 2×CA; 2×UHZ; 2×CL; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153 |
Heteromer P31947; | 88.89 | 4×U1B; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157 |
Heteromer P31947; | 88.89 | 2×V2E; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132 |
Heteromer P31947; | 88.89 | 2×GOL; 2×CL; 2×UG8; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123 |
Heteromer P31947; | 88.89 | 2×P7E; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121 |
Heteromer P31947; | 88.89 | 2×UWK; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122 |
Heteromer P31947; | 88.89 | 2×UWQ; 2×CA; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044 |
Heteromer P31947; | 88.89 | 2×CL; 2×TZK; 2×GOL; 4×CA; 2×MG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028 |
Heteromer P31947; | 88.89 | 2×CL; 2×P5Q; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033 |
Heteromer P31947; | 88.89 | 2×CL; 2×P6Z; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037 |
Heteromer P31947; | 88.89 | 2×CL; 2×P6H; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011 |
Heteromer P31947; | 88.89 | 2×CL; 2×P5N; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175 |
Heteromer P31947; | 88.89 | 2×CL; 2×TWE; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025 |
Heteromer P31947; | 88.89 | 2×CL; 2×L3S; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158 |
Heteromer P31947; | 88.89 | 2×CL; 2×V2Q; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161 |
Heteromer P31947; | 88.89 | 4×CL; 2×V32; 2×MG; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042 |
Heteromer P31947; | 88.89 | 4×CL; 2×V1E; 2×CA; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166 |
Heteromer P31947; | 88.89 | 2×CL; 2×V3N; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176 |
Heteromer P31947; | 88.89 | 4×CL; 2×V4H; 2×CA; 2×PEG; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164 |
Heteromer P31947; | 88.89 | 4×CL; 2×V3B; 4×PEG; 2×MG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173 |
Heteromer P31947; | 88.89 | 4×CL; 2×V3W; 2×CA; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041 |
Heteromer P31947; | 88.89 | 6×CL; 2×V1Q; 2×PEG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159 |
Heteromer P31947; | 88.89 | 2×CL; 2×V2T; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168 |
Heteromer P31947; | 88.89 | 4×CL; 2×V3T; 2×CA; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085 |
Heteromer P31947; | 88.89 | 4×CL; 2×V4B; 2×CA; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165 |
Heteromer P31947; | 88.89 | 4×CL; 2×V3K; 2×GOL; 2×CA; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027 |
Heteromer P31947; | 88.89 | 2×CL; 2×L3V; 2×CA; 2×MG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043 |
Heteromer P31947; | 87.5 | 2×V0Q; 2×MG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118 |
Heteromer P31947; | 87.5 | 2×CL; 2×GOL; 2×UHW; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128 |
Heteromer P31947; | 87.5 | 2×UGQ; 2×CL; 2×CA; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129 |
Heteromer P31947; | 87.5 | 2×P7T; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167 |
Heteromer P31947; | 87.5 | 4×CL; 2×V3Q; 2×MG; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045 |
Heteromer P31947; | 87.5 | 4×CL; 2×V1H; 2×MG; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178 |
Heteromer P31947; | 87.5 | 4×CL; 2×V4K; 2×CA; 2×GOL; | |||
Structure of importin a2 bound to p65-NLS |
Heteromer P52293; | 100 | ||||
14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046 |
Heteromer P31947; | 85.71 | 2×UQN; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119 |
Heteromer P31947; | 85.71 | 2×CL; 2×CA; 2×UHT; | |||
Crystal Structure of Brd4 Bromodomain 1 in Complex with Acetylated Rel Peptide |
Heteromer O60885; | 100 | ||||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160 |
Heteromer P31947; | 85.71 | 4×CL; 2×V2W; 2×MG; 2×GOL; | |||
14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110 |
Heteromer P31947; | 100 | 2×S9E; 2×PEG; | |||
Human SETD6 in complex with RelA Lys310 peptide |
Heteromer Q8TBK2; | 100 | 10×EDO; 1×SAM; | |||
Structure of importin a2 bound to the p50- and p65-NLSs |
Heteromer P19838; P52293; | 100 | ||||
Brd4 Bromodomain 2 in Complex with Acetylated Rel Peptide |
Heteromer O60885; | 100 | 1×DTT; | |||
14-3-3 sigma with RelA/p65 binding site pS281 |
Heteromer P31947; | 100 | ||||
Human SETD6 in complex with RelA Lys310 |
Heteromer Q8TBK2; | 100 | 1×SAM; 11×EDO; | |||
4 SWISS-MODEL models
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
9bdv.1.A | monomer | 0.84 | 97.21 | |||
1ooa.1.B | monomer | 0.76 | 44.60 | |||
1nfi.1.A | monomer | 0.76 | 99.67 | |||
2lww.1.B | monomer | 0.52 | 81.54 | |||
11 SWISS-MODEL models built on isoform sequence
Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|---|
Isoform 2 | 9bdv.1.A | monomer | 0.84 | 95.47 | |||
Isoform 2 | 1ooa.1.B | monomer | 0.77 | 44.76 | |||
Isoform 2 | 1nfi.1.A | monomer | 0.76 | 98.00 | |||
Isoform 2 | 2lww.1.B | monomer | 0.52 | 81.54 | |||
Isoform 3 | 9bdv.1.A | monomer | 0.82 | 97.11 | |||
Isoform 3 | 1nfi.1.A | monomer | 0.74 | 99.66 | |||
Isoform 3 | 1ooa.1.B | monomer | 0.73 | 45.85 | |||
Isoform 3 | 2lww.1.B | monomer | 0.51 | 81.54 | |||
Isoform 4 | 9bdv.1.A | monomer | 0.80 | 97.53 | |||
Isoform 4 | 1nfi.1.A | monomer | 0.75 | 98.99 | |||
Isoform 4 | 2lww.1.B | monomer | 0.52 | 81.54 | |||